Perfluorooctanoic acid and cardiovascular disease in US adults

Archives of Internal Medicine

Volumn 172, Issue 18, 2012, Pages 1397-1403

  Shankar, Anoop ^a   Xiao, Jie ^a   Ducatman, Alan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PERFLUOROOCTANOIC ACID;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SELF REPORT; SEX DIFFERENCE; SMOKING; UNITED STATES;

ADULT; CAPRYLATES; CARDIOVASCULAR DISEASES; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; HUMANS; MALE; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84867385331     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.3393     Document Type: Article

References (56)

1. US Environmental Protection Agency. Perfluorooctanoic acid (PFOA) and fluorinated telomers. http://www.epa.gov/oppt/pfoa/. Accessed May 5, 2010.
2. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007;99 (2):366-394. (Pubitemid 351753056)
3. Cui L, Zhou QF, Liao CY, Fu JJ, Jiang GB. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch Environ Contam Toxicol. 2009;56(2):338-349.
4. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the US population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect. 2007;115(11):1596-1602.
5. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115 (9):1298-1305. (Pubitemid 47471253)
6. Levy RI, Moskowitz J. Cardiovascular research: decades of progress, a decade of promise. Science. 1982;217(4555):121-129. (Pubitemid 12081413)
7. Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296(5568):695-698. (Pubitemid 34441988)
8. Grundy SM, D'Agostino RB Sr, Mosca L, et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation. 2001;104(4):491-496. (Pubitemid 32678283)
9. Nieto FJ. Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century. Am J Public Health. 1999;89(3):292-294.
10. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res. 2006;99(7):692-705. (Pubitemid 44498303)
11. Taylor AE. Cardiovascular effects of environmental chemicals. Otolaryngol Head Neck Surg. 1996;114(2):209-211. (Pubitemid 26064207)
12. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170(10):1268-1278.
13. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population. Environ Health Perspect. 2010;118(2):197-202.
14. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 2007; 49(10):1086-1096. (Pubitemid 350287341)
15. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med. 2007;49(8):872-879. (Pubitemid 47254709)
16. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 2007;81(2):231-246. (Pubitemid 47617455)
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-1847. (Pubitemid 28213628)
18. Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care. 2009;32(4):702-707.
19. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112-2119. (Pubitemid 46771048)
20. Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect. 2010; 118(2):229-233.
21. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283(18):2404-2410. (Pubitemid 30257539)
22. National Center for Health Statistics. National Health and Nutrition Examination Survey: reference manuals and reports. http://www.cdc.gov/nchs/ nhanes /nhanes2003-2004/nhanes03-04.htm. Accessed May 5, 2010.
23. Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008;300(11):1303-1310.
24. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-743. (Pubitemid 39056275)
25. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333-3341.
26. National Center for Health Statistics CfDC. Laboratory procedure manual for serum-creatinine. http://www.cdc.gov/nchs/data/nhanes/nhanes-03-04/l40-c-met -creatinine. pdf. Accessed May 6, 2010.
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(suppl 1):S64-S71.
28. Chobanian AV, Bakris GL, Black HR, et al Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. (Pubitemid 37553153)
29. Hanhijärvi H, Ophaug RH, Singer L. The sex-related difference in perfluorooctanoate excretion in the rat. Proc Soc Exp Biol Med. 1982;171(1):50-55.
30. Harada K, Saito N, Inoue K, et al. The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years. J Occup Health. 2004;46(2):141-147. (Pubitemid 38506782)
31. Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. Environ Res. 2005;99(2):253-261.
32. Schecter A, Colacino J, Haffner D, et al. Perfluorinated compounds, polychlorinated biphenyls, and organochlorine pesticide contamination in composite food samples from Dallas, Texas, USA. Environ Health Perspect. 2010;118(6):796-802.
33. Fernández Freire P, Pérez Martin JM, Herrero O, Peropadre A, de la Peña E, Hazen MJ. In vitro assessment of the cytotoxic and mutagenic potential of perfluorooctanoic acid. Toxicol In Vitro. 2008;22(5):1228-1233.
34. Liu C, Yu K, Shi X, et al. Induction of oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of freshwater tilapia (Oreochromis niloticus). Aquat Toxicol. 2007;82(2):135-143. (Pubitemid 46483734)
35. Yao X, Zhong L. Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. Mutat Res. 2005;587(1-2):38-44. (Pubitemid 41503579)
36. Hu W, Jones PD, DeCoen W, et al. Alterations in cell membrane properties caused by perfluorinated compounds. Comp Biochem Physiol C Toxicol Pharmacol. 2003; 135(1):77-88. (Pubitemid 36644994)
37. Qian Y, Ducatman A, Ward R, et al. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J Toxicol Environ Health A. 2010;73(12): 819-836.
38. Crist BL, Alekel DL, Ritland LM, Hanson LN, Genschel U, Reddy MB. Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women. J Womens Health (Larchmt). 2009;18(6):795-801.
39. Hanson M, Gluckman P. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart. 2005;91(7):864-866. (Pubitemid 40874067)
40. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93(3):621-635.
41. Kudo N, Mizuguchi H, Yamamoto A, Kawashima Y. Alterations by perfluorooctanoic acid of glycerolipid metabolism in rat liver. Chem Biol Interact. 1999; 118(1):69-83. (Pubitemid 29112822)
42. Van Rafelghem MJ, Vanden Heuvel JP, Menahan LA, Peterson RE. Perfluorodecanoic acid and lipid metabolism in the rat. Lipids. 1988;23(7):671-678.
43. Kudo N, Kawashima Y. Induction of triglyceride accumulation in the liver of rats by perfluorinated fatty acids with different carbon chain lengths: comparison with induction of peroxisomal beta-oxidation. Biol Pharm Bull. 2003;26(1):47-51. (Pubitemid 39663641)
44. DeWitt JC, Shnyra A, Badr MZ, et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol. 2009;39(1):76-94.
45. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94(9):1168-1178. (Pubitemid 38656403)
46. Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med. 2010;164(9):860-869.
47. Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in women exposed to perfluorocarbons. J Clin Endocrinol Metab. 2011;96(6):1747-1753.
48. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol. 2002;155(4):339-345. (Pubitemid 34132052)
49. Lin CY, Lin LY, Chiang CK, et al. Investigation of the associations between lowdose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol. 2010;105(6):1354-1363.
50. Lee DH, Silventoinen K, Hu G, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J. 2006;27(18):2170-2176. (Pubitemid 44412830)
51. Shankar A, Li J, Klein BE, Javier Nieto F, Klein R. Serum gamma-glutamyltransferase level and peripheral arterial disease. Atherosclerosis. 2008;199(1):102-109. (Pubitemid 351902197)
52. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect. 2010;118 (5):686-692.
53. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008; 148(11):832-845. (Pubitemid 351786932)
54. Anderson-Mahoney P, Kotlerman J, Takhar H, Gray D, Dahlgren J. Self-reported health effects among community residents exposed to perfluorooctanoate. New Solut. 2008;18(2):129-143.
55. Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology. 2009;20(6):921-928.
56. Genuis SJ, Birkholz D, Ralitsch M, Thibault N. Human detoxification of perfluorinated compounds. Public Health. 2010;124(7):367-375.